| |
| |
|
| Insider
Information: |
Korenberg Matthew E |
| Relationship: |
President & Chief Oper... |
| City: |
La Jolla |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
86,263 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$7,398,778 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
86,263 |
|
|
| Total
Value |
$7,398,778 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
President & Chief Oper... |
2024-05-14 |
86,263 |
2015-08-06 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
49 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2015-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2016-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,870 |
9,870 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
VP, Finance and CFO |
• – – |
2017-12-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,750 |
11,897 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2018-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,074 |
12,761 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2018-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,004 |
14,765 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,648 |
10,677 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,404 |
16,469 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2019-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,979 |
20,995 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2020-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
6,848 |
26,864 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2021-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
7,108 |
32,373 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,819 |
41,752 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
11,651 |
51,341 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2022-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
27,714 |
86,021 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2022-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
96,428 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
9,069 |
98,748 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
PRESIDENT & CHIEF OPERATING |
• – – |
2024-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
14,416 |
103,861 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
PRESIDENT & CHIEF OPERATING |
• – – |
2023-06-30 |
4 |
A |
$56.78 |
$21,349 |
D/D |
376 |
99,124 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
PRESIDENT & CHIEF OPERATING |
• – – |
2023-12-05 |
4 |
D |
$59.61 |
$118,266 |
D/D |
(1,984) |
97,140 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2022-12-28 |
4 |
D |
$66.29 |
$255,813 |
D/D |
(3,859) |
92,569 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
PRESIDENT & CHIEF OPERATING |
• – – |
2024-01-02 |
4 |
D |
$72.31 |
$210,928 |
D/D |
(2,917) |
94,223 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2022-11-30 |
4 |
D |
$72.90 |
$261,930 |
D/D |
(3,593) |
82,428 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & COO |
• – – |
2023-02-15 |
4 |
D |
$72.98 |
$210,912 |
D/D |
(2,890) |
89,679 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
PRESIDENT & CHIEF OPERATING |
• – – |
2024-02-15 |
4 |
D |
$74.65 |
$356,678 |
D/D |
(4,778) |
89,445 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
EVP,Finance & Strategy and CFO |
• – – |
2022-06-30 |
4 |
A |
$75.84 |
$12,437 |
D/D |
164 |
52,532 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & Chief Operating |
• – – |
2024-05-13 |
4 |
S |
$84.54 |
$290,828 |
D/D |
(3,440) |
100,421 |
0 |
% |
|
49 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
